Holen Sie sich die Stockscreener-App
1,142.85
0.61%
-7.00
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$1,149.85
Offen:
$1153.82
24-Stunden-Volumen:
2.04M
Relative Volume:
0.82
Marktkapitalisierung:
$1.02T
Einnahmen:
$72.25B
Nettoeinkommen (Verlust:
$25.28B
KGV:
41.14
EPS:
27.781
Netto-Cashflow:
$10.37B
1W Leistung:
-3.43%
1M Leistung:
-1.49%
6M Leistung:
+22.15%
1J Leistung:
+39.40%
1-Tages-Spanne:
$1,136.66
$1,164.92
1-Wochen-Bereich:
$1,136.66
$1,215.00
52-Wochen-Spanne:
$783.85
$1,292.65
Lilly Eli Co Stock (LLY) Company Profile
Firmenname
Lilly Eli Co
Sektor
Telefon
(317) 276-2000
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,142.85 | 1.02T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.03 | 623.34B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
262.82 | 459.33B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
144.30 | 354.80B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
141.00 | 268.10B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-17 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-12-16 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | Bestätigt | BofA Securities | Buy |
| 2025-12-15 | Bestätigt | Goldman | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-11-10 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Bestätigt | BMO Capital Markets | Outperform |
| 2025-10-14 | Hochstufung | Erste Group | Hold → Buy |
| 2025-09-17 | Herabstufung | Berenberg | Buy → Hold |
| 2025-08-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Herabstufung | Erste Group | Buy → Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-09-13 | Fortgesetzt | Citigroup | Buy |
| 2024-08-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Herabstufung | DZ Bank | Buy → Hold |
| 2024-02-16 | Bestätigt | Morgan Stanley | Overweight |
| 2023-12-21 | Herabstufung | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-20 | Fortgesetzt | UBS | Buy |
| 2023-08-09 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-26 | Bestätigt | Citigroup | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-24 | Bestätigt | BofA Securities | Buy |
| 2023-05-24 | Bestätigt | UBS | Buy |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-15 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-09-22 | Hochstufung | UBS | Neutral → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-03-10 | Eingeleitet | Daiwa Securities | Outperform |
| 2022-01-21 | Hochstufung | DZ Bank | Hold → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-16 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-16 | Bestätigt | BofA Securities | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-11 | Hochstufung | Berenberg | Hold → Buy |
| 2021-09-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-05 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-06-24 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-12-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-09-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-21 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2019-12-18 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-04-24 | Hochstufung | Edward Jones | Hold → Buy |
| 2019-04-11 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2019-01-23 | Eingeleitet | UBS | Buy |
| 2018-11-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-10-31 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-10-01 | Bestätigt | SunTrust | Buy |
| 2018-09-26 | Fortgesetzt | JP Morgan | Overweight |
Alle ansehen
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Eli Lilly stock after-hours at EUR 1,028.40: plus 0.07 percent versus prior close - AD HOC NEWS
‘India’s biotech ecosystem holds tremendous promise’: Eli Lilly CEO - The Economic Times
How Eli Lilly Just Extended Its Lead in the Weight-Loss Drug Market - Barron's
Foghorn Therapeutics Pivots Pipeline after Ending Eli Lilly Deal - AOL.com
Eli Lilly's Once-Daily Weight Loss Pill Orforglipron Shows Significant Reduction in Heart Disease Risk - Benzinga
Eli Lilly's Obesity Data Support Broader Portfolio Beyond Tirzepatide, UBS Says - marketscreener.com
Will Lilly (LLY) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research
Foghorn lays off 40% of staff after Lilly collaboration ends - biospace.com
Analyst recommendations: Alphabet, Amazon, Micron, Tesla, Eli Lilly… - marketscreener.com
BMO reiterates Eli Lilly stock Outperform on TRIUMPH-2 data By Investing.com - Investing.com UK
Eli Lilly presents Foundayo data. Eli Lilly and Company stock falls 1.18 percent - AD HOC NEWS
Why Is Eli Lilly (NYSE:LLY) Suddenly a Must-Watch Healthcare Stocks Stock Today? - Kalkine Media
Eli Lilly's Foundayo Shows Promising Results in Reducing Diabetes and Cardiovascular Risks (LLY) - GuruFocus
Eli Lilly's Foundayo Shows Major Diabetes Risk Reduction; LLY St - GuruFocus
Foghorn stock down as Lilly exits collaboration (FHTX:NASDAQ) - Seeking Alpha
Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease - PR Newswire
Eli Lilly stock pre-market at EUR 1,025.00: minus 0.26 percent - AD HOC NEWS
Eli Lilly's Ebglyss Phase 3 Success Highlights Growth Potential for LLY - GuruFocus
Eli Lilly Loses Full Fed. Circ. Bid To Nix Teva's $177M IP Win - Law360
Lilly combo drug cuts weight up to 23% in trial - Briefs Finance
Eli Lilly's Foundayo Shows Cardiovascular Benefits in Phase 3 Tr - GuruFocus
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study - PR Newswire
Experimental Lilly combination drug tops Zepbound in weight-loss trial - reuters.com
Missed Out On The Eli Lilly & Novo Nordisk GLP-1 Boom? These 7 Stocks Could Benefit Next! - Stocks Down Under
Doctors condemn big pharma's move to dispense GLP-1s to your door - ABC News & Headlines – Australian Broadcasting Corporation
Lilly's retatrutide GLP-1 delivers average weight loss of 50 pounds - USA Today
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo - Fierce Biotech
Eli Lilly Data Shows Retatrutide Promotes Weight Loss Over Eighty Weeks - Benzinga
Eli Lilly's EloraTZP Shows Promising Weight Loss Results in Mid-Stage Trial (LLY) - GuruFocus
Eli Lilly unveils compelling Phase 2b results for its EloraTZP combination - marketscreener.com
Eli Lilly (LLY) Reports Promising Phase 2b Results for EloraTZP in Obesity and Type 2 Diabetes - GuruFocus
Eli Lilly’s Zepbound combined with amylin drug led to significant weight loss in mid-stage trial - statnews.com
Eli Lilly (LLY) Reports Promising Phase 2b Trial Results for Elo - GuruFocus
Eloralintide: Eli Lilly's New Obesity Treatment Shows Promising Results - GuruFocus
Eli Lilly stock rises on striking 23% weight loss in drug combo trial - Investing.com
What's Behind Eli Lilly's (NYSE:LLY) Big Moment in Healthcare Stocks Today? - Kalkine Media
Tirzepatide or Semaglutide? Novo Nordisk Says Higher Semaglutide Dose Shows Cardiovascular Edge Over Eli - Benzinga
Lilly Drug Combo Spurs Record Weight Loss in Diabetes Study - Bloomberg.com
Lilly's EloraTZP (combination of eloralintide and tirzepatide) delivered greater weight loss and A1C reduction vs. tirzepatide 15 mg in adults with obesity and type 2 diabetes - Eli Lilly
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial - cnbc.com
Eli Lilly's Ebglyss Shows Strong Phase 3b Results for Atopic Der - GuruFocus
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - GlobeNewswire Inc.
Is Eli Lilly and Co (LLY) a Bargain After 0.0% Drop? GF Value Sa - GuruFocus
Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Eli Lilly (LLY) Reports Strong TRIUMPH-2 Trial Results for Retat - GuruFocus
Eli Lilly Stock Barely Moved Following Viking Therapeutics' Impressive Clinical Results. Here's Why. - The Motley Fool
Eli Lilly’s Experimental Weight-Loss Drug Shows Promising Results - yahoo.com
Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro - reuters.com
Wegovy or Zepbound? Eli Lilly Shows Zepbound Outperforms Wegovy in New Weight Loss Data - yahoo.com
Lilly Says Higher-Dose Zepbound Just Widened Its Lead Over Wegovy - Yahoo Finance
Lilly touts Foundayo advantage over Novo's Ozempic pill in diabetes analysis - reuters.com
Finanzdaten der Lilly Eli Co-Aktie (LLY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.02%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):